BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim CW, Kim CS, Kim HY, Lee CD, Yu K, Llamoso C, Lee HJ. Large-scale surveillance study of the safety and effectiveness of entecavir in Korean patients with chronic hepatitis B. Korean J Intern Med 2018;33:91-101. [PMID: 29228519 DOI: 10.3904/kjim.2016.111] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Cho EJ, Yu SJ, Kwon SY, Kim JH, Kim DY, Kim W, Lee JS, Lee JW, Lee YJ, Chae HB, Yoon JH. Concomitant food intake does not affect the efficacy of entecavir in chronic hepatitis B patients with virological response: a randomized, multicenter, noninferiority trial. Drug Des Devel Ther 2018;12:3767-74. [PMID: 30464407 DOI: 10.2147/DDDT.S181561] [Reference Citation Analysis]
2 Pan CQ, Afdhal NH, Ankoma-Sey V, Bae H, Curry MP, Dieterich D, Frazier L, Frick A, Hann HW, Kim WR, Kwo P, Milligan S, Tong MJ, Reddy KR. First-line therapies for hepatitis B in the United States: A 3-year prospective and multicenter real-world study after approval of tenofovir alefenamide. Hepatol Commun 2022. [PMID: 35445803 DOI: 10.1002/hep4.1964] [Reference Citation Analysis]